While Novartis holds a diversified product portfolio, there is some product concentration with its largest drugs, Entresto (close to 15% of sales) and Cosentyx (close to 10% of sales). Both drugs will ...

Novartis stock made a break for a buy point Tuesday after the drugmaker beat first-quarter expectations and raised its full-year outlook.

FDA granted an accelerated approval for Vanrafia for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression. Vanrafia can be ...

Ad hoc announcement pursuant to Art. 53 LR Net sales grew +15% (cc1, +12% USD) with core operating income1 up +27% (cc, +23% USD) Sales growth driven by continued strong performance from Entresto ...

A clinical trial of an intrathecal formulation of spinal muscular atrophy gene therapy Zolgensma has also been put on hold, leaving Novartis in need of “positive pipeline news”, said Welford.

During an earnings call, the firm reported strong sales for Pluvicto and other precision medicines and elaborated on its US manufacturing plans.

Novartis reports strong Q1 2025 with $13.2B in sales, beating forecasts. Key drugs Xolair, Zolgensma, Kisqali exceed ...

Novartis India Limited (NIL) is a subsidiary of Swiss giant Novartis the world's second largest pharmaceutical company was incorporated on 13 December 1947. The Company is engaged in manufacturing and ...